Lupin Ltd. NSE: LUPIN | BSE: 500257

Strong Performer, Getting Expensive

In 2 Starfolio Baskets

Download real time

2066.80 -32.00 (-1.52%)

1.3M

NSE+BSE Volume

NSE 08 Dec, 2025 3:27 PM (IST)

Lupin Corporate Filings & Announcements

Latest corporate announcements and filings from Lupin on BSE

Search Inside the pdf :

05 Dec 2025

2066.80

-1.52%

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Lupin Receives Tentative Approval from U.S. FDA for Siponimod Tablets.

04 Dec 2025

2066.80

-1.52%

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Lupin and Valorum Enter into an Exclusive Licensing Agreement for Biosimilar Armlupeg (Pegfilgrastim-unne) in the United States.

01 Dec 2025

2066.80

-1.52%

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)

BSE India

Lupin Receives Approval from U.S. FDA for Biosimilar Armlupeg (Pegfilgrastim-unne).

28 Nov 2025

2066.80

-1.52%

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Lupin Foundation Earns CRISIL''s Highest VO 1A Rating for Excellence in Social Responsibility.

21 Nov 2025

2066.80

-1.52%

Company Update

Lupin Ltd - 500257 - U.S. FDA Has Conducted An Inspection At Company''s Manufacturing Facility Located …

BSE India

U.S. FDA has conducted an inspection at Company''s manufacturing facility located at Goa, India.

15 Nov 2025

2066.80

-1.52%

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Lupin announces Closure of Inspection by U.S. FDA at its Nagpur Unit-1 Facility with No Observations.

14 Nov 2025

2066.80

-1.52%

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT Exclusivity in the U.S., the first product from its proprietary Long-Acting Injectable platform PrecisionSphere.

13 Nov 2025

2066.80

-1.52%

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Lupin Establishes a New Global Standard in Sustainable Pharma with an S&P Global ESG Score of 91.

12 Nov 2025

2066.80

-1.52%

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Lupin Receives EIR from U.S. FDA for its Aurangabad (CSN) Facility

12 Nov 2025

2066.80

-1.52%

Earnings Call

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Transcript of Q2 FY2026 Earnings Conference Call.

Is Lupin Ltd. worth buying?

931 Votes:

Buy 72.72%

Sell 17.62%

Hold 9.67%

RESEARCH REPORTS

Buy SEE REPORTS >

Buy SEE REPORTS >